Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis

[1]  A. Lichtenstein,et al.  EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study. , 2020, Atherosclerosis.

[2]  Morten Wang Fagerland,et al.  Effects of n-3 Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized Controlled Trial. , 2020, Circulation.

[3]  D. Mozaffarian,et al.  Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. , 2020, JAMA.

[4]  C. Lavie,et al.  Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials. , 2020, Mayo Clinic proceedings.

[5]  Deepak L. Bhatt,et al.  Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial , 2020, European heart journal.

[6]  Deepak L. Bhatt,et al.  Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Deepak L. Bhatt,et al.  Reduction in Revascularization With Icosapent Ethyl , 2020, Circulation.

[8]  D. Mutch,et al.  EPA and DHA have divergent effects on serum triglycerides and lipogenesis, but similar effects on lipoprotein lipase activity: a randomized controlled trial. , 2019, The American journal of clinical nutrition.

[9]  Deepak L. Bhatt,et al.  REDUCE-IT USA , 2019, Circulation.

[10]  Jennifer G. Robinson,et al.  Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. , 2019, Circulation.

[11]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[12]  E. Guallar,et al.  Effects of Nutritional Supplements and Dietary Interventions on Cardiovascular Outcomes , 2019, Annals of Internal Medicine.

[13]  Deepak L. Bhatt,et al.  Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. , 2019, Journal of the American College of Cardiology.

[14]  Deepak L. Bhatt,et al.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.

[15]  J. Manson,et al.  Marine n‐3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer , 2019, The New England journal of medicine.

[16]  Michael E. Miller,et al.  Effect of losartan and fish oil on plasma IL-6 and mobility in older persons. The ENRGISE Pilot randomized clinical trial. , 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.

[17]  F. Song,et al.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. , 2018, The Cochrane database of systematic reviews.

[18]  R. Collins,et al.  Effects of n‐3 Fatty Acid Supplements in Diabetes Mellitus , 2018, The New England journal of medicine.

[19]  B. Bistrian,et al.  Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial , 2017, Journal of the American Heart Association.

[20]  I. Kubota,et al.  A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. , 2017, Journal of cardiology.

[21]  S. Lehéricy,et al.  Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial , 2017, The Lancet Neurology.

[22]  A. D'Angelo,et al.  Effects of n-3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. , 2016, BioFactors.

[23]  Hiroshi Ito,et al.  Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. , 2016, International journal of cardiology.

[24]  L. March,et al.  Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose , 2015, Annals of the rheumatic diseases.

[25]  F. Grodstein,et al.  Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. , 2015, JAMA.

[26]  S. Proudman,et al.  Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis , 2015, British Journal of Nutrition.

[27]  J. Brophy,et al.  Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. , 2014, Journal of the American College of Cardiology.

[28]  O. Cummings,et al.  No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. , 2014, Gastroenterology.

[29]  G. Steinbeck,et al.  Effects of 1-year treatment with highly purified omega-3 fatty acids on depression after myocardial infarction: results from the OMEGA trial. , 2013, The Journal of clinical psychiatry.

[30]  Dana Waichunas,et al.  A Randomized Placebo-Controlled Pilot Trial of Omega-3 Fatty Acids and Alpha Lipoic Acid in Alzheimer’s Disease , 2013, Journal of Alzheimer's disease : JAD.

[31]  R. Newcombe,et al.  Implementing GRADE: calculating the risk difference from the baseline risk and the relative risk , 2013, Evidence-Based Medicine.

[32]  P. Ducimetiere,et al.  Cardiovascular effects of B-vitamins and/or N-3 fatty acids: the SU.FOL.OM3 trial. , 2013, International journal of cardiology.

[33]  M. Roncaglioni,et al.  n-3 fatty acids in patients with multiple cardiovascular risk factors. , 2013, The New England journal of medicine.

[34]  D. Ferrante,et al.  Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. , 2013, Journal of the American College of Cardiology.

[35]  C. Ballantyne,et al.  Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). , 2012, Journal of clinical lipidology.

[36]  C. Ballantyne,et al.  Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). , 2012, The American journal of cardiology.

[37]  S. Yusuf,et al.  n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. , 2012, The New England journal of medicine.

[38]  M. Garg,et al.  Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. , 2012, Heart rhythm.

[39]  Simon G Thompson,et al.  Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews , 2012, International journal of epidemiology.

[40]  M. Binns,et al.  Impact of low v. moderate intakes of long-chain n-3 fatty acids on risk of coronary heart disease , 2011, British Journal of Nutrition.

[41]  J. Geleijnse,et al.  n-3 fatty acids and cardiovascular events after myocardial infarction. , 2010, The New England journal of medicine.

[42]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[43]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[44]  A. Cohen,et al.  Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. , 2008, JAMA.

[45]  C. Ballantyne,et al.  Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. , 2007, Clinical therapeutics.

[46]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[47]  R. Hauer,et al.  Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. , 2006, JAMA.

[48]  I. Hjermann,et al.  Effect of diet or very long chain ω-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[49]  C. Sirtori,et al.  Effect of n‐3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: A double‐blind pilot study in primary prevention , 2006, Annals of medicine.

[50]  M. Josephson,et al.  Prevention of Fatal Arrhythmias in High-Risk Subjects by Fish Oil n-3 Fatty Acid Intake , 2005, Circulation.

[51]  P. Calder,et al.  Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. , 2005, Reproduction, nutrition, development.

[52]  S. Chugh,et al.  Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. , 2005, JAMA.

[53]  Andrea Furlan,et al.  Updated Method Guidelines for Systematic Reviews in the Cochrane Collaboration Back Review Group , 2003, Spine.

[54]  B. Bistrian.  Clinical aspects of essential fatty acid metabolism: Jonathan Rhoads Lecture. , 2003, JPEN. Journal of parenteral and enteral nutrition.

[55]  G. Albrektsen,et al.  Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. , 2001, The American journal of clinical nutrition.

[56]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[57]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[58]  P. Stone,et al.  Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. , 1995, Journal of the American College of Cardiology.

[59]  M. Robertson,et al.  Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. , 1990, Australian and New Zealand journal of medicine.

[60]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[61]  W. Schunck,et al.  Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. , 2011, Biochimica et biophysica acta.

[62]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[63]  L. Tavazzi,et al.  ect of n-3 polyunsaturated fatty acids in patients with chronic heart failure ( the GISSI-HF trial ) : a randomised , double-blind , placebo-controlled trial , 1980 .

[64]  G. Brattebø,et al.  A long-term seal- and cod-liver-oil supplementation in hypercholesterolemic subjects , 2001, Lipids.

[65]  P. Angerer,et al.  The effect of n−3 fatty acids on coronary atherosclerosis: Results from SCIMO, an angiographic study, background and implications , 2001, Lipids.

[66]  K. Grønseth,et al.  Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. , 1996, The American journal of cardiology.